Investigating the metabolic effects of antiretroviral drugs in people living with HIV
Official title: Multiomics and Antiretroviral Drug Exposure for assessing Metabolic Effects (MADE-FOR-ME)
Funded at University of Pittsburgh at Pittsburgh · NIH-11087674 · Data updated 2026-11-12
This study is looking at how HIV treatment affects heart health and metabolism in people living with HIV, aiming to understand the link between ongoing inflammation from the virus and the risk of heart disease, so we can find better ways to keep your heart healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | May 15, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $522,167 |
| NIH project number | 5DP1HL174180-02 |
| Project ID | NIH-11087674 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are undergoing antiretroviral therapy.
✕Less likely to help
Patients who are not living with HIV or those who are not receiving antiretroviral therapy may not benefit from this research.
What this research studies
This research focuses on understanding how antiretroviral therapy (ART) affects metabolic health in individuals living with HIV. It aims to identify the relationship between persistent inflammation caused by HIV and the increased risk of cardiovascular disease (CVD) in these patients. By analyzing stored biological samples, the study will explore the impact of various inflammatory biomarkers and antiretroviral drug exposure on cardiometabolic health. The goal is to provide insights that could lead to better risk assessment and targeted interventions for managing cardiovascular health in people with HIV.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for reducing cardiovascular disease risk in individuals living with HIV.
How similar studies have gone: Previous research has shown that understanding the metabolic effects of antiretroviral therapy can lead to significant advancements in managing cardiovascular risks in HIV patients.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Devanathan, Aaron Sriram — University of Pittsburgh at Pittsburgh
- Study coordinator: Devanathan, Aaron Sriram
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.